Fate Therapeutics Inc revenue
Fate Therapeutics Inc's revenue was $6.6m in fiscal 2025, down 51.2% on the year before. Since fiscal 2011 ($1.2m) it has grown at a compound 14.3% a year. Over the last twelve months it was $6.5m.
Revenue history
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 3 | 1 | 2 | 4 | 4 | 5 | 11 | 31 | 56 | 96 | 64 | 14 | 7 | 6 |
| Growth on the year before | — | +128.2% | −63.6% | +150.4% | +81.1% | −6.7% | +15.4% | +125.3% | +194.3% | +77.7% | +72.4% | −34.0% | −78.5% | −51.2% | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Fate Therapeutics Inc | $6.5m | -23.4% | -62.1% |
| HCW Biologics Inc. | $6.7m | 700.2% | 20.4% |
| CG Oncology, Inc. | $6.2m | 1030.3% | — |
| Tscan Therapeutics, Inc. | $7.1m | 2.2% | -24.3% |
| Evaxion A/s | $7.5m | 125.1% | — |
| Roivant Sciences Ltd. | $7.5m | -67.6% | -46.4% |
Compare with peers
- HCW Biologics Inc. revenue
- CG Oncology, Inc. revenue
- Tscan Therapeutics, Inc. revenue
- Evaxion A/s revenue
- Roivant Sciences Ltd. revenue
Head to head: FATE vs HCWBCGON vs FATEFATE vs TCRX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies